Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tracy Bridges

Allergy & Immunology Albany, GA Medical Doctor

NPI 1386749117 CMS profile 16964

105 Spanish Crt, Albany, GA 31707

Open in the dashboard

General payments

$364,257

892 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,165,131 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Tracy Bridges of Albany, GA is reported in the CMS Open Payments database as having received $364,257 across 892 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,165,131 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $81,412 190
2024 General $89,402 169
2023 General $58,854 146
2022 General $29,070 96
2021 General $37,125 97
2020 General $23,755 91
2019 General $44,639 103

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tracy Bridges
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Tracy Bridges were reported at $81,412. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Tracy Bridges Allergy & Immunology median Middle half National median
2019 $44,639 $594 $163–$1,512 $163
2020 $23,755 $426 $106–$1,233 $114
2021 $37,125 $638 $157–$1,708 $132
2022 $29,070 $790 $205–$1,961 $149
2023 $58,854 $852 $220–$2,147 $160
2024 $89,402 $865 $203–$2,267 $164
2025 $81,412 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $257,126 284 payments
  2. Regeneron Healthcare Solutions, Inc. $36,140 88 payments
  3. Amgen Inc. $26,282 47 payments
  4. Genzyme Corporation $11,694 23 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $7,960 41 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $7,513 20 payments
  7. Shire North American Group Inc $4,700 16 payments
  8. Grifols USA, LLC $2,735 28 payments
  9. Teva Pharmaceuticals USA, Inc. $1,872 21 payments
  10. GlaxoSmithKline, LLC. $1,769 113 payments
  11. Other $6,467 211 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $319,858 134 payments
  2. Food and Beverage $19,778 656 payments
  3. Travel and Lodging $17,781 89 payments
  4. Consulting Fee $6,737 11 payments
  5. Education $103 2 payments
Products named General payments · program years 2019–2025
  1. TEZSPIRE Respiratory $130,135 126 payments
  2. AIRSUPRA $96,514 100 payments
  3. DUPIXENT Inflammation And Immunology $35,837 81 payments
  4. TEZSPIRE Inflammation $18,114 41 payments
  5. FASENRA $16,596 26 payments
  6. DUPIXENT Immunology $6,224 29 payments
  7. DUPIXENT Immunology $5,731 5 payments
  8. CUVITRU $5,616 37 payments
  9. Xembify $2,591 21 payments
  10. ProAir Digihaler $1,748 9 payments
  11. Other $16,518 459 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

5,153

Median for Allergy/ Immunology: 449

Drug cost

$2,518,137

Median for Allergy/ Immunology: $169,700

Branded share of claims

25.8%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Haegarda C1 Esterase Inhibitor Brand 26 $839,912
Dupixent Syringe Dupilumab Brand 99 $389,003
Tezspire Tezepelumab-Ekko Brand 54 $234,446
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 218 $172,054
Xolair Omalizumab Brand 50 $165,528
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 31 $161,904
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 12 $125,699
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 79 $56,759
Dupixent Pen Dupilumab Brand 14 $49,107
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 11 $45,204

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$180,534

Of which drugs: $114,877

Medicare patients

320

Average age 74

Services billed

12,422

220 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 31%
Chronic kidney disease 26%
COPD 23%
Depression 23%
Ischemic heart disease 22%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
$47,043 — —
TEZSPIRE
$40,704 54 —
DUPIXENT
$382 113 —
TRELEGY ELLIPTA
$165 218 —
CUVITRU
$160 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

892 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record